Bad blood: secrets and lies in a Silicon Valley startup
(Book)
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
Notes
Carreyrou, J. (2018). Bad blood: secrets and lies in a Silicon Valley startup. First edition. New York, Alfred A. Knopf.
Chicago / Turabian - Author Date Citation (style guide)Carreyrou, John. 2018. Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Alfred A. Knopf.
Chicago / Turabian - Humanities Citation (style guide)Carreyrou, John, Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Alfred A. Knopf, 2018.
MLA Citation (style guide)Carreyrou, John. Bad Blood: Secrets and Lies in a Silicon Valley Startup. First edition. New York, Alfred A. Knopf, 2018.
Record Information
| Last Sierra Extract Time | Apr 16, 2024 10:18:27 AM |
|---|---|
| Last File Modification Time | Apr 16, 2024 10:21:48 AM |
| Last Grouped Work Modification Time | Apr 27, 2024 10:19:06 PM |
MARC Record
| LEADER | 03640nam 2200553 i 4500 | ||
|---|---|---|---|
| 003 | CPomAG | ||
| 005 | 20190411080139.0 | ||
| 008 | 180316t20182018nyu b 001 0 eng | ||
| 010 | |a 2018000263 | ||
| 019 | |a 1019646846 | ||
| 020 | |a 9781524731656|q (hardcover) | ||
| 020 | |a 152473165X|q (hardcover) | ||
| 037 | |b Random House Inc, Attn Order Entry 400 Hahn rd, Westminster, MD, USA, 21157|n SAN 201-3975 | ||
| 040 | |a MvI-LONL|b eng|c MvI-LONL | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 049 | |a MRQA | ||
| 050 | 0 | 0 | |a HD9995.H423|b U627 2018 |
| 082 | 0 | 0 | |a 338.7/681761|2 23 |
| 084 | |a BUS025000|a BUS027000|a TEC059000|2 bisacsh | ||
| 099 | |a 338.7 CAR | ||
| 100 | 1 | |a Carreyrou, John,|e author. | |
| 245 | 1 | 0 | |a Bad blood :|b secrets and lies in a Silicon Valley startup /|c John Carreyrou. |
| 250 | |a First edition. | ||
| 264 | 1 | |a New York :|b Alfred A. Knopf,|c 2018. | |
| 300 | |a x, 339 pages ;|c 25 cm | ||
| 336 | |a text|b txt|2 rdacontent | ||
| 337 | |a unmediated|b n|2 rdamedia | ||
| 338 | |a volume|b nc|2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue. | |
| 520 | |a In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley. | ||
| 596 | |a 2 4 5 6 8 9 10 14 17 19 20 21 24 29 30 31 33 34 37 40 42 44 45 | ||
| 598 | |a MLINEWBKS, MMINEWBKS | ||
| 600 | 1 | 0 | |a Holmes, Elizabeth Anne,|d 1984- |
| 610 | 2 | 0 | |a Theranos (Firm)|x History. |
| 650 | 0 | |a Hematologic equipment industry|z United States. | |
| 650 | 0 | |a New business enterprises|x Corrupt practices|z United States|v Case studies. | |
| 650 | 0 | |a Securities fraud|z United States|v Case studies. | |
| 650 | 7 | |a BUSINESS & ECONOMICS / Entrepreneurship.|2 bisacsh | |
| 650 | 7 | |a BUSINESS & ECONOMICS / Finance.|2 bisacsh | |
| 650 | 7 | |a TECHNOLOGY & ENGINEERING / Biomedical.|2 bisacsh | |
| 650 | 7 | |a Fraud.|2 fast|0 (OCoLC)fst00933786 | |
| 650 | 7 | |a Hematologic equipment industry.|2 fast|0 (OCoLC)fst00954898 | |
| 651 | 7 | |a United States.|2 fast|0 (OCoLC)fst01204155 | |
| 655 | 7 | |a History.|2 fast|0 (OCoLC)fst01411628 | |
| 907 | |a .b27588257 | ||
| 945 | |y .i69299249|i 34342001311022|l lyan|s -|h |u 0|x 0|w 0|v 0|t 2|z 12-19-23|o -|a 338.7 CAR | ||
| 998 | |e -|d a |f eng|a ly | ||
